Oppenheimer analyst Jay Olson raised the firm’s price target on Sage Therapeutics (SAGE) to $25 from $23 and keeps a Perform rating on the shares. The firm notes Sage reported Q4 results with $77.9M total revenue, which includes a $75.0M one-time milestone payment from partner Biogen (BIIB) upon the first commercial sale of Zurzuvae in PPD, $119.2M OpEx, and $753.2M cash expected to provide runway into 2026. Sage highlighted several promising signals that support its confidence in the Zurzuvae launch, which Oppenheimer views as supporting its incremental optimism in the longer-term commercial opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- Bad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been Added
- Sage Therapeutics expects cash available will support its operations into 2026
- Sage Therapeutics reports Q4 EPS (55c), consensus ($1.28)
- SAGE Earnings this Week: How Will it Perform?
- Sage Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
